glp 1 pediatric GLP-1R Agonists in Children GLP-1RAs improve ALT in pediatric

Description

There have been and continue to be advances in the GLP-1 pipeline.

Very few include older adults at high risk

From the approval of Orlistat (Xenical) in 1999, which focused on reducing dietary fat absorption, to the emergence of highly effective incretin-based therapies such as liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound), we have witnessed a fundamental shift in how obesity is understood and treated

For local players, this reinforces the role of licensing and distribution alliances as a practical path to compete in the global #obesity market ahead of full-scale innovation or manufacturing build-out

Meals and snacks with GLP-1 Friendly labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and Zepbound to lose weight.